LipoGlo: A sensitive and specific reporter of atherogenic lipoproteins

James H. Thierer[1,2], Stephen C. Ekker[3] and Steven A. Farber[1,2]*

[1]Carnegie Institution for Science Department of Embryology, Baltimore, MD 21218

[2]Johns Hopkins University Department of Biology, Baltimore, MD 21218 [3] Mayo Clinic Department of Biochemistry and Molecular Biology, Rochester, MN 55905

ABSTRACT:

Apolipoprotein-B (APOB) is the structural component of atherogenic lipoproteins, lipid-rich particles that drive atherosclerosis by accumulating in the vascular wall. As atherosclerotic cardiovascular disease is the leading cause of death worldwide, there is an urgent need to develop new strategies to prevent lipoproteins from causing vascular damage. Here we report the LipoGlo system, which uses a luciferase enzyme (NanoLuc) fused to ApoB to monitor several key determinants of lipoprotein atherogenicity including particle abundance, size, and localization. Using LipoGlo, we are able to comprehensively characterize the lipoprotein profile of individual larval zebrafish and collect the first images of atherogenic lipoprotein localization in an intact organism. We discover multiple unexpected extravascular lipoprotein localization patterns, as well as identify *pla2g12b* as a potent regulator of lipoprotein size. ApoB-fusion proteins thus represent a uniquely sensitive and specific approach to study atherogenic lipoproteins and their genetic and small molecule modifiers.

KEYWORDS:

Lipoprotein, Apolipoprotein-B, ApoB, atherosclerosis, cardiovascular disease, zebrafish, pla2g12b

29

30

31 **INTRODUCTION:**

32 ApoB-containing lipoproteins (ABCLs) are the etiological agents of atherosclerotic
33 cardiovascular disease [1], which is the leading cause of mortality worldwide [2]. ABCLs serve to shuttle
34 lipids throughout the circulation, but occasionally cross the vascular endothelium to form lipid-rich
35 deposits within the vascular wall that develop into atherosclerotic plaques [1]. ABCLs are frequently
36 characterized indirectly through measurement of their triglyceride and cholesterol content, and high-risk
37 individuals with elevated lipid levels are prescribed lipid-lowering therapies such as statins [3]. Such
38 drugs effectively reduce cardiovascular disease risk by lowering the levels of cholesterol carried by
39 atherogenic lipoproteins (often called “bad cholesterol”).

40 Indirect (lipid-focused) measurements, however, provide very limited information on ABCL
41 properties such as particle concentration or size distribution, both of which are key determinants of
42 atherogenic potential. For example, serum Apolipoprotein-B (ApoB) levels directly reflect the
43 concentration of ABCL particles and show a stronger correlation with cardiovascular disease risk than
44 lipid metrics (including cholesterol) [4, 5]. The size distribution of lipoprotein particles is also relevant to
45 cardiovascular disease risk, as there are numerous classes of ABCLs that can be differentiated by size
46 and show varying degrees of atherogenicity [6]. Low-density lipoproteins (LDL) are the smallest and
47 most abundant class of ABCLs and are thought to be the primary drivers of atherosclerosis. There is
48 significant size variation within the LDL particle class, and smaller particles are associated with
49 increased atherogenicity [7]. For example, approximately 25% of the adult population produces
50 unnaturally small LDL particles, and as a result have ~3-fold higher risk for cardiovascular disease [8].

51 Many of the genetic and environmental factors governing ABCL size and abundance remain
52 undiscovered or poorly characterized [9-11], and even fewer have been successfully targeted
53 pharmaceutically [12-14]. It has proven particularly difficult to identify drugs that modulate ABCL size
54 and abundance because the simplified model systems (such as cultured cells or invertebrate models)
55 typically used in high-throughput drug screening do not recapitulate the complex multi-organ physiology
56 responsible for ABCL homeostasis. While lipoproteins are studied extensively in mammalian models,

these systems are not conducive to high-throughput drug discovery. By contrast, the larval zebrafish model system has proven to be a powerful system for *in vivo* drug discovery, as it recapitulates all major aspects of vertebrate physiology in a small, transparent, rapidly developing organism. However, no existing assays are sensitive enough to characterize ABCLs in individual larval zebrafish [15-17], as each larvae contains only a few nanoliters of plasma.

Here we present the LipoGlo reporter as a remarkably sensitive and tractable new tool to study atherogenic lipoproteins. Modern genome engineering techniques were used to fuse the endogenous ApoB gene in zebrafish with an engineered luciferase reporter (NanoLuc), such that each atherogenic lipoprotein would be tagged with a light-emitting molecule. Using this reporter, we were able to develop several independent assays to characterize distinct aspects of the ABCL profile (summarized in Fig. 1a). These include a plate-based assay to measure lipoprotein quantity (LipoGlo-Counting), a gel-based assay to measure lipoprotein size (LipoGlo-Electrophoresis), and chemiluminescent imaging to visualize lipoprotein localization (LipoGlo-Microscopy).

We also performed extensive validation of these assays *in vivo* by showing conserved responses to genetic, pharmacological, and dietary manipulations in living zebrafish (summarized in Fig. 1b). Finally, we leveraged the discovery potential of these assays to identify previously uncharacterized associations between ABCLs and the central nervous system [18], as well as identify the poorly characterized gene *pla2g12b* [19] as a potent regulator of lipoprotein particle size that is conserved across vertebrates.

LipoGlo was developed first in larval zebrafish as this organism is uniquely well-suited for high-throughput genetic and small molecule screening, as well as whole-organism imaging. However, LipoGlo represents a highly generalizable tool that can be expanded to function in essentially any organism with atherogenic lipoproteins, and customized with different reporters depending on the research question. This technique has the potential to transform our understanding of atherogenic lipoprotein biology, which may have important clinical repercussions in the treatment of atherosclerotic cardiovascular disease.



Figure 1:
Overview of LipoGlo assays and experimental manipulations. **(a)** Individual larvae carrying the ApoB-NanoLuc reporter are first homogenized in ABCL stabilization buffer. Homogenate can be used for LipoGlo-Counting (a plate-based assay for NanoLuc activity to measure the total number of ABCLs), LipoGlo-Electrophoresis (a Native-PAGE assay to determine the ABCL size/subclass distribution), and DNA extraction for genotyping. Alternatively, lipoprotein density and size can be determined by density-gradient ultracentrifugation on pooled samples (DGUC) followed by electron microscopy. To determine localization of ABCLs *in situ*, individual larvae are fixed in 4% PFA and mounted in low-melt agarose for chemiluminescent imaging (LipoGlo-Microscopy). Asterisk indicates that electrophoretic mobility is an indirect measure of particle size. **(b)** ApoB protein fused to NanoLuc is loaded with lipid through the activity of Mtp to form VLDL particles. In the absence of lipidation, the protein will be rapidly degraded by ERAD. VLDL is lipolyzed by serum lipases that use Apoc2 as an obligate cofactor to produce smaller lipoprotein classes such as LDL. Here we investigate the effects of (i) genetic manipulations (mutations in *mtp* and *apoC2*), (ii) dietary variation (fasting and feeding), and (iii) pharmacological treatment (inhibition of Mtp with lomitapide) on various aspects of the ABCL profile.

85 **RESULTS:**

86

87 **TALEN-mediated genome engineering enables creation of the LipoGlo reporter**

88 ApoB is an ideal scaffold for creating a reporter of ABCLs. It is both an obligate structural
89 component present in single copy on each lipoprotein particle [20], and is rapidly degraded when not
90 associated with an ABCL via endoplasmic-reticulum-associated protein degradation (ERAD) [21]
91 (Fig. 1b). In mammals there is a single *APOB* gene that can be post-transcriptionally edited into two
92 isoforms: the full-length *APOB-100* expressed primarily in the liver, and the truncated *APOB-48*
93 isoform expressed in the intestine [22, 23]. Although the zebrafish genome contains 3 paralogs of
94 *APOB*, a single paralog (*apoBb.1*) is the clearly dominant isoform, accounting for approximately 95%
95 of the *ApoB* mRNA and protein in larval zebrafish [24]. Known functional elements of ApoB are well
96 conserved in zebrafish, including both the microsomal triglyceride transfer protein (MTP) interacting
97 [25] and LDL-receptor binding [26] domains (Supplementary Fig. 1a). However, the APOB-48 editing
98 site required for production of the truncated (intestine-specific) version of APOB [23] appears to be
99 completely absent in zebrafish (Supplementary Fig. 1b). This creates the opportunity to
100 simultaneously tag both intestine and liver derived ABCLs with a carboxy-terminal fusion to ApoBb.1
101 in zebrafish.

102 NanoLuc is an optimized luciferase reporter that generates a quantitative chemiluminescent
103 signal through cleavage of its substrate molecule, furimazine [27]. This reporter is remarkably bright
104 (~100 times brighter than firefly luciferase), small (19.1 kDa), stable, and provides robust signal to
105 noise ratios that enable accurate detection even at femtomolar concentrations [27]. The NanoLuc
106 coding sequence was introduced as a carboxy-terminal fusion to the endogenous ApoBb.1 gene in
107 zebrafish through homology directed repair of a double-stranded break [28]. Capped mRNA
108 encoding a TALEN pair targeting the ApoBb.1 stop codon was co-injected with a donor DNA
109 construct to induce homology-directed repair. The donor construct contains the NanoLuc coding
110 sequence flanked on either side by several hundred base pairs of sequence homologous to the
111 genomic sequence upstream and downstream of the ApoBb.1 stop codon (Supplementary Fig. 2).
112 Injected embryos were raised to adulthood and their progeny were screened for NanoLuc activity

113 and subsequently for error-free integration at the target locus. The resulting tagged lipoproteins are
114 quantified using the Nano-Glo assay (Promega Corp., N1110), which led us to name this system
115 LipoGlo.
116 Fish homozygous for the LipoGlo reporter are healthy, fertile, and do not display any
117 abnormal morphological or behavioral phenotypes. Additionally, larvae homozygous for the LipoGlo
118 reporter show a two-fold increase in LipoGlo signal relative to their heterozygous siblings
119 (Supplementary Fig. 2c). Together, these data suggest that the LipoGlo reporter does not disrupt
120 normal production, secretion, and turnover of lipoprotein particles.
121
122
123 **LipoGlo-Counting reveals changes in ABCL abundance**
124 The LipoGlo-Counting method uses a 96-well plate based assay to detect NanoLuc activity
125 and quantify ABCL abundance. In order to validate the LipoGlo reporter and evaluate the degree of
126 similarity between zebrafish and mammalian lipoprotein homeostasis, the lipoprotein profile was
127 assayed across development, as well as in response to genetic, pharmacological, and dietary
128 manipulation (Fig. 1b). Individual larvae carrying the LipoGlo reporter are homogenized in a
129 standard volume of ABCL stabilization buffer (100 μL) using either a pellet pestle for low throughput
130 sample processing (Fisher scientific, 12-141-363), or a microplate horn sonicator for processing of
131 96 samples simultaneously in plate format (QSonica, 431MPX). The ABCL stabilization buffer
132 contains protease inhibitors, pH buffers, and cryoprotectant to ensure sample stability during
133 processing and storage. A portion of the homogenate (40 μL) is mixed with an equal volume of
134 Nano-Glo assay buffer and quantified in a plate reader. The remaining homogenate is either stored
135 frozen for later use, or used for additional assays (Fig. 1a).
136 ABCL levels were measured throughout development from 1 – 6 days post-fertilization (dpf)
137 using zebrafish carrying the LipoGlo reporter in the wild-type (WT) genetic background (Fig. 2a).
138 During this window of development, embryos are in the lecithotropic (yolk-metabolizing) stage [29].
139 All nutrients required for development are provided by the maternally deposited yolk, until the yolk
140 becomes depleted between 5 and 6 dpf and the larvae begin to rely on exogenous food. Yolk lipid is



Figure 2:
LipoGlo-Counting reveals conserved ABCL responses to genetic, dietary, and pharmacological stimuli. (a) LipoGlo signal throughout WT larval zebrafish development (1 – 6 dpf). Time points designated with different letters are statistically significantly different (n=24, ANOVA p<0.0001, Tukey's HSD p<.0001). **(b)** Comparison of LipoGlo signal between *mtp*$^{-/-}$ mutants (defective in lipoprotein synthesis) and *mtp*$^{+/-}$ siblings during larval development (n≈16, Two-way robust ANOVA p<0.0001 for genotype and stage, Games-Howell p<.001). **(c)** Comparison of LipoGlo signal between *apoC2*$^{-/-}$ mutants (defective in lipoprotein breakdown) and *apoC2*$^{+/-}$ siblings during larval development (n≈12, Two-way robust ANOVA p<0.0001 for genotype and stage, Games-Howell p<.0001). **(d)** Effect of lomitapide (10 µM, Mtp inhibitor) on LipoGlo signal (3 – 5 dpf) (n=30, Two-way robust ANOVA p<0.0001 for treatment and time, Games-Howell p<.0001). **(e)** LipoGlo levels were measured over time throughout a fast, re-feed, and chase period. Larvae were fed a standard diet *ad libitum* from 5 to 10 dpf, and then were deprived of food for 48 hours (fast period). Larvae were then fed a high-fat (5% egg yolk) diet for 6 hours, transferred to fresh media, and assayed at various time points for the 72 hours following the onset of feeding (48-120 hours) (n=30, Welch's ANOVA p<0.0001, Games-Howell p<.0001). Results represent pooled data from three independent experiments, "n" denotes number of samples per data point.

141 packaged into ABCLs by the yolk syncytial layer (YSL), a specialized embryonic organ that
142 expresses many genes involved in ABCL production including *ApoBb.1* [24]. Accordingly, ABCL
143 levels are quite low early in development, but increase between 1 – 3 dpf as more yolk lipid is
144 packaged into ABCLs (Fig. 2a). As the larvae are not provided with food, ABCL levels drop later in
145 development as rates of lipoprotein metabolism and turnover exceed rates of production following
146 yolk depletion.

147 LipoGlo reporter fish were then crossed with fish harboring mutations in essential
148 components of the ABCL production and breakdown pathways. Microsomal Triglyceride Transfer
149 Protein (Mtp) is responsible for loading nascent ApoB with lipid to form ABCLs [30], and
150 Apolipoprotein-C2 (ApoC2) is a cofactor for lipoprotein lipolysis [31] (outlined in Fig. 1b). As
151 expected, *mtp*$^{-/-}$ mutants [32] exhibit profound defects in ABCL production detectable from the
152 earliest stages of development (Fig. 2b). By contrast, *apoC2*$^{-/-}$ mutants [15] produce lipoproteins
153 normally but show significantly reduced levels of particle breakdown and turnover compared to
154 sibling controls (Fig. 2c).

155 To probe the effects of transient Mtp inhibition on larval lipoprotein homeostasis, larvae were
156 exposed to lomitapide. Lomitapide is a pharmaceutical inhibitor of Mtp used to treat familial
157 hypercholesterolemia in humans [33]. Larvae were treated with 10 μM lomitapide or vehicle control
158 for 48 h (3-5 dpf), and treated larvae showed a more rapid decline in NanoLuc levels than vehicle-
159 treated controls. This observation is consistent with lomitapide inhibiting ABCL production and
160 leading to an accelerated decline of ApoB-NanoLuc levels (Fig. 2d).

161 To test the effect of food intake on ABCL levels, larvae were subjected to a fasting and re-
162 feeding experimental paradigm. Larvae were fed a standard diet (Gemma 75, Skretting USA) for 5
163 days (from 5-10 dpf) to adapt to food intake and reach a physiologically relevant baseline level of
164 ABCLs. Following the initial feeding period, larvae were fasted for 48 h (sampled every 12 h), re-fed
165 with a high-fat meal of 5% egg-yolk [34], and sampled at various time points after the meal (the
166 chase period). ApoB-NanoLuc levels were stable for the first 12 h of the fast, but declined rapidly for
167 the duration of the fasting period (Fig. 2e, 0-48 h). Following the high fat meal (6 h of feeding from
168 time point 48 h to time point 54 h), there was an immediate increase in ApoB-NanoLuc levels (Fig.

169 2e, 48-120 hrs). ApoB-NanoLuc levels did not recover to their pre-fasted state following the high-fat
170 meal, but rather remained at an intermediate level for a prolonged period (the duration of the chase
171 period, 72 h).
172
173 **Determination of lipoprotein size distribution using LipoGlo-Electrophoresis**
174 There are numerous classes of ABCLs, many of which can be differentiated based on
175 particle size [35]. Native polyacrylamide gel electrophoresis (Native-PAGE) has previously been
176 used to separate ABCLs based on size, but requires a relatively large volume of plasma (25 μL)
177 stained with lipophilic dyes [36]. The LipoGlo-Electrophoresis method subjects crude larval
178 homogenate (containing only nanoliters of plasma) to Native-PAGE to separate lipoproteins,
179 followed by in-gel detection of NanoLuc activity. To analyze the ABCL size distribution over
180 development and in response to genetic, pharmacological, and dietary manipulations, representative
181 frozen aliquots of larval homogenate from a given condition were thawed on ice. A portion of the
182 thawed homogenate (12 μL) was mixed with 5x loading dye (3 μL) and separated via Native-PAGE
183 (3% gel for 275 Volt-h). Following separation, the glass front plate was removed to expose the gel
184 surface, and 1 mL of TBE containing Nano-Glo substrate solution (2 μL) was added to the plate and
185 spread evenly using a thin plastic film. The gel was then imaged using the Odyssey Fc
186 chemiluminescent detection system (LI-COR Biosciences). Together, this protocol is referred to as
187 LipoGlo electrophoresis.
188 Smaller lipoproteins are expected to migrate further into the gel, and larger lipoproteins to
189 show concomitantly less mobility (Fig. 3a). Following electrophoretic separation, ABCLs can be
190 divided into four different classes based on their migration distance. ABCLs that remain within the
191 loading well are classified as the “zero mobility” (ZM) fraction, which should include chylomicrons
192 [37], remnants, aggregates [38], and intracellular ApoB complexed with components of the secretory
193 pathway (such as the ER, golgi, and other secretory vesicles) [39]. Species that do migrate into the
194 gel are classified as either Very Low-Density Lipoproteins (VLDL), Intermediate-Density Lipoproteins
195 (IDL), or Low-Density Lipoproteins (LDL) based on their electrophoretic mobility. Di-I-Labeled
196 fluorescent LDL (L3482, ThermoFisher Scientific) is used as a migration standard to ensure



Figure 3:
Changes in lipoprotein size distribution revealed through LipoGlo-Electrophoresis. (a) Representative image of the fluorescent DiI-LDL migration standard and LipoGlo emission from WT, *mtp*$^{-/-}$, and *apoC2*$^{-/-}$ genotypes (4 dpf). ABCLs are divided into 4 classes based on their mobility, including ZM (zero mobility) and three classes of serum ABCLs (VLDL, IDL, LDL). Image is a composite of chemiluminescent (LipoGlo, blue) and fluorescent (DiI-LDL, orange) exposures. Gel is a representative image from one of the three independent experiments performed. **(b)** Vertical plot profile generated in ImageJ from gel image displayed in (a), note that the ZM peak has been appended to highlight differences in serum lipoprotein classes. **(c-e)** Representative gel images (one of three independent experiments shown) and **(f-h)** pooled LipoGlo-electrophoresis quantification data from larval lysates used in Figure 2. Relative abundance of subclasses is color-coded as shown in (a). Upward-facing arrowheads (green) indicate significant enrichment of that species at that time point compared to controls, and downward-facing arrowheads (red) indicate depletion **(f)** Subclass abundance at each day of larval development in WT (n=9, Welch's ANOVA $p<0.0001$ for each subclass over time), *mtp*$^{-/-}$ (n=9, Two-way robust ANOVA $p<0.001$ for VLDL and LDL, Games-Howell $p<.01$), and *apoC2*$^{-/-}$ (n=9, Two-way robust ANOVA $p<0.01$ for all classes, Games-Howell $p<.005$) genetic backgrounds. **(g)** Subclass abundance from 3-5 dpf in larvae treated with 10µM lomitapide or vehicle control (n=9, Two-way robust ANOVA $p<0.001$ for all classes except IDL, Games-Howell $p<.01$). **(h)** Subclass abundance from 10-15 dpf in larvae subjected to a fasting and re-feeding paradigm. The first bracket delineates changes relative to time 0 (the onset of the fasting period), and the second bracket delineates changes relative to time point 48 (the onset of the re-feeding period) (n=9, Welch's ANOVA $p<0.0001$ for each subclass over time, Games-Howell $p<.01$). Supplementary Figure 4 displays standard deviations for panels f-h. Results represent pooled data from three independent experiments, "n" denotes number of samples per data point.

197 consistent classification of ABCL species between gels, with the migration distance of this species
198 corresponding to one ladder unit (L.U.). Although the Di-I stain significantly reduces electrophoretic
199 mobility of the human LDL and therefore does not align with NanoLuc-labeled LDL (data not shown),
200 this band provides a highly reproducible standard for registration and normalization across gels
201 (Supplementary Fig. 3).

202 In order to define physiologically relevant migration boundaries between ABCL classes,
203 ABCL profiles were compared for WT, *mtp*$^{-/-}$, and *apoC2*$^{-/-}$ mutant lines at 4 dpf (Fig. 3a,b). *ApoC2*$^{-/-}$
204 mutants are unable to lipolyze VLDL, which allowed us to define the VLDL bin from .3 – 1 ladder
205 units. Conversely, *mtp*$^{-/-}$ mutants display a bimodal peak of small LDL-like particles at this stage of
206 development, which was used to define the LDL bin as 1.7 – 2.4 ladder units from the origin. Wild-
207 type larvae have a peak of intermediate-sized lipoproteins at this stage, which corresponds to the
208 IDL region from 1 – 1.7 ladder units. ABCLs migrating less than .3 ladder units were considered to
209 be in the zero-mobility fraction (ZM) (Fig. 3a).

210 Gel images were transformed into plot profiles in ImageJ for quantification (Fig. 3b). The
211 provided Gel Quantification Template (supplementary file 1) contains instructions and formulas for
212 automatically calculating bin cutoffs for each ABCL class based on the migration of the Di-I standard
213 and quantifying the relative intensity of each bin. To visualize the distribution of ABCL classes over
214 time, each species was color coded with darker colors corresponding to smaller lipoproteins and
215 plotted as an 100% stacked area chart (Fig. 3f-h). Upward-facing green arrowheads or downward-
216 facing red arrowheads are used to indicate which species show significant enrichment or depletion
217 (respectively) relative to the control group (Fig. 3f-h). Additional plots were generated that present
218 these data grouped by ABCL class (rather than genotype) (Supplementary Fig. 4).

219 Using LipoGlo-Electrophoresis over the course of zebrafish larval development revealed that
220 in the early embryonic stages (1-2 dpf), the wild-type ABCL profile is dominated by VLDL (Fig. 3c,f),
221 which are directly produced by the YSL. By 3 and 4 dpf, these VLDL particles have been lipolyzed to
222 generate the smaller IDL and LDL classes. When the maternal yolk has been depleted (5-6 dpf) and
223 in the absence of exogenous food, VLDL production is significantly attenuated as indicated by the
224 enrichment of the small lipolyzed lipoproteins. The ABCL profile dynamics are much more static in

225 the *mtp*$^{-/-}$ and *apoC2*$^{-/-}$ mutant lines. *mtp*$^{-/-}$ mutants produce smaller IDL and LDL-like particles from
226 the earliest stages of development, and *apoC2*$^{-/-}$ mutants show a VLDL peak that persists
227 throughout development (Fig. 3c,f). Consistent with the data from *mtp*$^{-/-}$ mutants, pharmacological
228 treatment with a potent MTP inhibitor (Lomitapide) effectively blocks the production of new VLDL
229 particles (Fig. 3d,g) leading to the accumulation of lipolyzed species such as IDL and LDL.
230 Consistent with the mammalian literature, a robust post prandial response to a high lipid meal
231 (egg yolk emulsion) was observed in the distribution of ABCL subclasses of larval zebrafish (Fig.
232 3e,h). After fasting (48 h), there is significant depletion of VLDL and enrichment of LDL, consistent
233 with cessation of VLDL production due to limited nutrient availability. A subsequent high-fat meal
234 produces a significant increase in the ZM band, and progressive depletion of LDL.
235
236 **Electrophoretic mobility correlates well with lipoprotein density and size**
237 Electrophoretic mobility in Native-PAGE is a function of both size and charge, so it is
238 important to evaluate whether differences in migration truly reflect different lipoprotein sizes or if
239 they are the result of differentially charged lipoproteins. Density gradient ultracentrifugation (DGUC)
240 is the gold standard for discerning different subclasses of ABCLs, as larger lipoprotein classes are
241 more buoyant resulting from their large lipid core. To evaluate concordance between DGUC and the
242 LipoGlo assays, we developed a DGUC protocol (based on the method described by Yee et al., [40])
243 to separate pooled larval homogenate into density fractions. We then subjected fractions to (i)
244 LipoGlo electrophoresis to characterize their electrophoretic mobility, (ii) a plate read assay to
245 quantify ApoB-NanoLuc levels, and (iii) negative-staining electron microscopy to visualize particle
246 size directly [41] (Fig. 4). Importantly, denser fractions showed higher electrophoretic mobility and
247 smaller particle sizes across all genotypes, demonstrating that electrophoretic mobility is a reliable
248 method for differentiating ABCL classes and can be used as a proxy to estimate particle size and
249 density.
250
251 **LipoGlo-Microscopy reveals whole-organism ABCL localization**
252 The transparency of larval zebrafish offers the unique opportunity to perform whole-mount



Figure 4:
Concordance between LipoGlo electrophoresis and classical ABCL size characterization techniques. DGUC was performed on pooled larval homogenate (4 dpf) from WT, *mtp*$^{-/-}$, and *apoC2*$^{-/-}$, and separated into 10 equal fractions of approximately 500 µL each by drip-elution (dense bottom fractions eluted first). **(a)** Fractions 2-10 were subjected to Native-PAGE, and denser fractions showed higher electrophoretic mobility. Some fractions show a faint lower mobility band (indicated at right by white arrowhead), possibly indicative of lipoprotein dimerization. **(b)** A plate-based assays of NanoLuc activity revealed the expected enrichment of VLDL in *apoC2*$^{-/-}$ mutants, and enrichment of LDL in *mtp*$^{-/-}$ mutants (confirming results reported in Fig. 3b). **(c)** A refractometer (Bausch and Lomb) was used to determine the refractive index of each fraction and density was calculated via the formula D = 3.3508 x RI - 3.4675. DGUC showed highly reproducible density profiles between replicates and genotypes. **(d)** The density of WT fractions 4 – 9 was plotted as a function of peak electrophoretic mobility for that fraction, and the second order polynomial function (y = 0.0796x2 - 0.1886x + 1.136) was able to represent this relationship with remarkable accuracy (R^2 = 0.97737) indicating that electrophoretic mobility is a useful proxy for lipoprotein density. **(e)** Fractions 4, 7, and 10 were subjected to negative-staining electron microscopy to directly visualize the size of particles in each fraction. In the wild type samples, the average particle diameter was 24.7±5.6, 29.0±4.1, and 34.9±4.7 nm for fractions 4, 7, and 10 respectively. There was no significant difference in particle size between fraction 4 of the wild-type and *mtp*$^{-/-}$ mutant samples (average diameter of 23.2 ± 6.6 nm). Particles were nearly undetectable in fractions 7 and 10 in the *mtp*$^{-/-}$ mutant sample so particle diameter shows enormous variability. ABCLs in each *apocC2*$^{-/-}$ mutant fraction were significantly larger than all WT fractions, with diameters of 39.0±8.0, 40.9±7.2, and 39.1±5.9 nm respectively (n≈170, Welch's ANOVA p<0.0001, Games-Howell p<.0001). **(f)** Representative images of lipoproteins from the three wild-type fractions are shown. **(g)** The second-order polynomial function y= 10.82x2 - 44.551x + 70.125 approximated the relationship between electrophoretic mobility and density in wild-type samples with reasonable accuracy (R^2 = 0.79978). Results represent pooled data from four independent experiments.

253 imaging, which has enabled us to perform the first characterization of changes in ABCL localization
254 throughout an intact organism. The same developmental, genetic, dietary, and pharmacological
255 manipulations described above (Figs. 2-3) were performed, but rather than being homogenized,
256 larvae were fixed in 4% paraformaldehyde (PFA) for 3 h at room temperature, washed in PBS-
257 tween, and mounted in low-melt agarose [42] supplemented with Nano-Glo substrate solution.
258 Mounted larvae were imaged in a dark room on a Zeiss Axiozoom V16 equipped with a Zeiss
259 AxioCam MRm set to collect a single brightfield exposure followed by multiple exposures with no
260 illumination (chemiluminescent imaging).

261 The differences between WT, *mtp*$^{-/-}$, and *apoC2*$^{-/-}$ mutants were most apparent at 6 dpf (Fig.
262 5a). At this stage, the yolk is depleted and larvae are in a fasted state as no exogenous food has
263 been provided. In WT larvae, signal is quite low throughout the body, but is clearly visible in the
264 lipoprotein-producing tissues (liver and intestine). We observed a previously undescribed
265 association of ApoB with the spinal cord (Fig. 5b, and Supplementary Fig. 5a) as evidenced by
266 colocalization with the central-nervous system marker *Tg(Xla.Tubb2:mApple-CAAX*). This reporter
267 uses the tubulin beta-2 promoter from *X. Laevis* to drive a membrane-targeted mApple fluorophore
268 specifically in the CNS. A dorsal view revealed enrichment of NanoLuc signal in particular brain regions
269 (Fig. 5c), which we hypothesize may correspond to the brain ventricle. In *mtp*$^{-/-}$ mutants, ApoB is
270 very low outside of the lipoprotein-producing tissues, consistent with defects in loading ApoB with
271 lipid to form a secretion-competent ABCL. *ApoC2*$^{-/-}$ mutants show remarkably high signal throughout
272 the body, consistent with their inability to process and turnover lipoproteins (Fig. 5a).

273 Images were quantified by creating separate regions of interest for the viscera, trunk, and
274 head regions (Supplementary figure 5c) and comparing the relative levels of NanoLuc signal in each
275 of these areas. During development, signal was initially highly enriched in the visceral region, which
276 contains the yolk and YSL, and then gradually increases in the trunk and head regions (Fig. 5d,g).
277 This is consistent with the vectorial transport of lipid from the YSL to the circulatory system and
278 peripheral tissues. The distribution of ApoB between these three regions was not significantly
279 changed in *apoC2*$^{-/-}$ mutants, whereas *mtp*$^{-/-}$ mutants showed enrichment in the viscera and



Figure 5:
Whole-mount imaging of ABCL localization using LipoGlo chemiluminescent microscopy. (a) Representative images of ABCL localization patterns from analysis of 15 larvae per genotype from WT, *mtp*$^{-/-}$, and *apoC2*$^{-/-}$ genotypes (6 dpf). The white arrow and arrowhead mark the larval intestine and liver respectively. **(b)** LipoGlo signal colocalizes with the central nervous system marker *Tg(Xla. Tubb2-mApple-CAAX)*, quantification in Supplementary Figure 5. **(c)** LipoGlo signal localized to subregions of the CNS. **(d-f)** Representative images and **(g-i)** quantification of ABCL localization across developmental, genetic, pharmacological, and dietary manipulations. Upward-facing arrowheads (green) indicate significant enrichment of that species at that time point compared to controls, and downward-facing arrowheads (red) indicate depletion. **(g)** Signal localization at each day of larval development in WT (n=15, Welch's ANOVA $p<0.0001$ for each region over time), *mtp*$^{-/-}$ (n=15, Two-way robust ANOVA $p<0.001$ for all regions, Games-Howell $p<0.001$), and *apoC2*$^{-/-}$ (n=15, Two-way robust ANOVA was not significant for any region) genetic backgrounds. **(h)** Signal localization from 3-5 dpf in larvae treated with 10µM lomitapide or vehicle control (n=15, Two-way robust ANOVA $p<0.001$ for head and viscera, Games-Howell $p<.0001$). **(i)** Subclass abundance from 10-15 dpf in larvae subjected to a fasting and re-feeding paradigm. The first bracket delineates changes relative to time 0 (the onset of the fasting period), and the second bracket delineates changes relative to time point 48 (the onset of the re-feeding period) (n=15, Welch's ANOVA $p<0.0001$ for each region, Games-Howell $p<.005$). Supplementary Figure 4 displays standard deviations for panels g-i. Results represent pooled data from three independent experiments, "n" denotes number of samples per data point. Body regions were defined as outlined in Supplementary Figure 5. Scale bars = 500 µm.

280 depletion in the peripheral tissues at all time points (Fig. 5d,g). Results were also grouped by region
281 to facilitate comparison of each class between genotypes (Supplementary Fig. 4).
282
283 **LipoGlo assays reveal Pla2g12b as an important regulator of ABCL homeostasis**
284 In an effort to identify novel regulators of the ABCL profile using the LipoGlo system, we
285 screened through several mutant lines from the zebrafish mutation project [43] that had predicted
286 mutations in genes involved in lipid metabolic pathways. Larvae homozygous for an essential splice
287 site mutation (sa659) in phospholipase A2 Group XII B (*pla2g12b*) showed perturbations in their
288 ABCL profile (Fig. 6). Homozygous mutant larvae exhibited lower levels of ApoB at multiple stages
289 (Fig. 6a), and also appeared to have defects in lipoprotein secretion as evidenced by enrichment of
290 visceral ApoB-NanoLuc levels (Fig. 6b,e). However, the most striking defect in *pla2g12b*$^{-/-}$ mutant
291 larvae is a pronounced change in the ABCL size distribution. Even at 1 dpf, significant accumulation
292 of small lipoproteins in the size range of LDL, and depletion of the larger particle classes, were
293 evident (Fig. 5c,d).
294
295 **DISCUSSION:**
296
297 **The LipoGlo reporter does not disrupt lipoprotein homeostasis**
298 When generating a fusion protein, it is essential to evaluate whether introduction of the tag
299 disrupts native protein function. This is particularly important in the case of tagged lipoproteins, as
300 these particles have a complex life cycle that involves interaction with numerous cell and tissue types.
301 To evaluate whether the NanoLuc tag disrupted lipoprotein homeostasis, LipoGlo larvae were
302 subjected to various genetic, dietary, and pharmacological manipulations known to affect the lipoprotein
303 profile. Detailed characterization of the lipoprotein profile in response to each of these stimuli revealed
304 the expected results in each case. These results validate that NanoLuc-tagged lipoproteins exhibit all of
305 the central hallmarks of endogenous ABCLs, including MTP-dependent maturation, APOC2-dependant
306 lipolysis, responsiveness to nutrient availability, and expected density and size distributions.



Figure 6:
LipoGlo reveals profound alterations in the ABCL profile in *pla2g12b*$^{-/-}$ mutant larvae. (a) Comparison of LipoGlo signal between *pla2g12b*$^{-/-}$ and *pla2g12b*$^{+/-}$ siblings during larval development (1 – 6 dpf) (n≈11, Two-way robust ANOVA p<0.0001 for genotype and stage, Games-Howell p<.0001). **(b)** Representative images (n=15) of ABCL localization collected by LipoGlo chemiluminescent imaging throughout development (1 – 6 dpf), and **(e)** quantification of percent localization into previously described subregions (n=15, Two-way robust ANOVA p<0.001 for all regions, Games-Howell p<0.0001). **(c)** Representative gel (n=4) showing production of abnormally small lipoproteins (white arrowhead) with a lane of the 4 dpf WT profile (reproduced from Fig. 3a) provided for reference. **(d)** Quantification of LipoGlo emission pattern from LipoGlo electrophoresis in *pla2g12b*$^{-/-}$ larvae (1 – 6 dpf). Upward-facing arrowheads (green) indicate significant enrichment of that species at that time point compared to WT, and downward-facing arrowheads (red) indicate depletion (n=9, Two-way robust ANOVA p<0.001 for all species, Games-Howell p<.01). Results represent pooled data from three independent experiments, "n" denotes number of samples per data point. Body regions were defined as outlined in Supplementary Figure 5. Scale bars = 500 µm.

307 These observations establish a precedent for the use of ApoB-fusion proteins as a sensitive and
308 specific approach to monitor atherogenic lipoproteins *in vivo*. This approach can now be generalized to
309 function in essentially any model system expressing ApoB, and expanded to use alternative tags such
310 as fluorescent reporters for high-resolution imaging or affinity tags to study the lipoprotein interactome.
311 Potential applications of LipoGlo thus extend well beyond the study of lipoprotein abundance, size, and
312 localization using zebrafish.
313
314 **LipoGlo assays show excellent concordance with existing methods**
315 Atherogenic lipoproteins are the primary drivers of atherosclerotic cardiovascular disease, which
316 has made lipoprotein profiling an essential technique in both clinical and research settings. Existing
317 methods to characterize ABCLs generally rely on large amounts of starting material (microliters of
318 plasma), use indirect measurements (e.g. lipid profiling), require expensive equipment and specialized
319 training (e.g. an ultracentrifuge or electron microscope), have a relatively low throughput capacity, and
320 are restricted to studying plasma lipoproteins. The LipoGlo reporter circumvents all of these issues and
321 engenders unprecedented speed, sensitivity, and tractability to the study of the lipoprotein profile.
322 Importantly, these assay shows excellent concordance with traditional methods, as evidenced by the
323 tight correlation between particle size estimates measured by LipoGlo electrophoresis and both density
324 gradient ultracentrifugation and negative-staining electron microscopy.
325 One limitation of the LipoGlo electrophoresis method reported here is that it is unable to
326 resolve ABCLs above a certain size threshold, which are clustered together as the zero-mobility
327 fraction. Further research will thus be required to conclusively determine which lipoprotein species
328 are present within this band. For example, this band is highly enriched in response to a high-fat
329 meal. This observation is consistent with enrichment of intracellular ApoB and the largest lipoprotein
330 classes (chylomicrons and remnants), both of which should increase in response to high-fat diet. It is
331 interesting to note, however, that when lipoproteins are processed through tandem density gradient
332 ultracentrifugation and LipoGlo-electrophoresis, there is significant signal in the ZM fraction even in
333 the higher density fractions. This indicates that the ZM band is not exclusively composed of very
334 large triglyceride-rich lipoproteins, but also includes additional denser species. We suspect this may

335 reflect the physiological level of lipoprotein aggregation, which has been implicated as yet another
336 determinant of cardiovascular disease risk.
337
338 **The larval zebrafish is a powerful new system to study lipoprotein biology**
339 The LipoGlo system is significantly more sensitive than existing lipoprotein characterization
340 assays. To illustrate this, we have performed extensive lipoprotein characterization on individual
341 zebrafish larvae. A single larva contains approximately one-thousand times less plasma (nanoliters
342 rather than microliters) than is traditionally used for lipoprotein profiling, yet this is more than enough
343 material to run multiple LipoGlo assays. The larval zebrafish has been used extensively to study
344 metabolic diseases including cardiovascular disease [44], but the inability to characterize the
345 atherogenic lipoprotein profile in this model presented a significant limitation. LipoGlo enabled
346 comprehensive characterization of the atherogenic lipoprotein profile throughout larval development,
347 which will serve as a valuable resource for the zebrafish research community. LipoGlo was also used to
348 demonstrate numerous similarities in lipoprotein processing between larval zebrafish and humans.
349 The larval zebrafish is also an unparalleled vertebrate system for high-throughput screening.
350 The simple plate-based LipoGlo-counting method enables processing of tens of thousands samples a
351 day, and is thus readily conducive to high-throughput genetic and small-molecule screening. The
352 LipoGlo-electrophoresis and imaging protocols can also achieve respectable throughput capacity on
353 the order of hundreds of samples per day, and can thus be used as tractable secondary screening
354 assays or for stand-alone small-scale screens. The confluence of LipoGlo and the zebrafish model
355 system create the first opportunity to perform unbiased screens for novel modulators of ABCLs,
356 enabling powerful unbiased discovery approaches to be applied to the field of lipoprotein biology.
357
358 **Sensitive lipoprotein profiling may provide new insights into abetalipoproteinemia**
359 Human mutations in the *mtp* gene result in severe reduction or complete lack of ABCLs, a
360 disease called abetalipoproteinemia. The mtp^{stl} allele studied contains a single missense mutation in a
361 highly conserved residue (L475P) [32]. Although this is thought to result in production of a non-
362 functional protein, a true null allele would be expected to result in a complete lack of ABCLs. The mtp^{stl}

363 homozygous mutants are unequivocally able to produce and secrete a ABCLs (although they are
364 smaller and less abundant) early in development, although at the later stages ABCLs are essentially
365 undetectable. These observations suggest that the *mtp*^{stl} allele is either a strong hypomorph, or that
366 ABCLs can be produced without the activity of Mtp. The complete lack of ABCLs later in development
367 occurs once rates of particle turnover and uptake begin to greatly exceed rates of production. This
368 observation highlights the LipoGlo system as a useful tool to study allelic series of *mtp*. By studying
369 different alleles at the earliest stages of development when rates of lipoprotein turnover are low, it may
370 be possible to distinguish between true null alleles and varying degrees of hypomorphic mutations.
371 Such information would be useful in predicting the severity of different abetalipoprotienemia mutations
372 in humans.

373 Additionally, the *mtp*$^{-/-}$ mutants produce a distinct bimodal peak of small (LDL-like) ABCLs (Fig.
374 3a-c). This pattern warrants further investigation, but may indicate that these alleles directly produce
375 small lipoproteins from the YSL, which are subsequently lipolyzed to produce the second peak. Further
376 study of this allele may provide insight into the specific functional domains of MTP that regulate the size
377 of nascent ABCLs.

378

379 **Organ-level changes in lipoprotein localization**

380 The localization of atherogenic lipoproteins throughout an intact organism has not previously
381 been reported. Several observations were in line with our expectations, in that lipoproteins were clearly
382 visible in lipoprotein-producing tissues such as the liver, intestine, and yolk-syncytial layer. Lipoproteins
383 were also clearly evident throughout the circulatory system as expected. However, one of the most
384 striking patterns of lipoprotein localization is the chevron pattern outlining the somites in the trunk
385 region. We suspect this pattern may correspond to the myosepta [45], which include tendinous
386 structures connecting the body segments. Lipoproteins have previously been shown to accumulate in
387 tendons in cases of severe hyperlipidemia [46], but these images suggest that an unexpectedly large
388 fraction of ABCLs localize to these structures in a normal physiological state. The physiological
389 consequences of this association are still unknown, but suggest that the pool of non-circulating ABCLs
390 cannot be ignored in studies of whole-body energy homeostasis.

391 In addition to this somite pattern, surprisingly strong LipoGlo signal was also observed in the
392 central nervous system (both the brain and spinal cord), colocalizing with the CNS marker
393 *Tg(Xla.Tubb2:mapple-CAAX*). While this pattern was evident throughout development, it was most
394 pronounced in larvae that have low levels of atherogenic lipoproteins throughout the body (such as
395 wild-type larvae at 6 dpf, or larvae that have been fasted or treated with lomitapide for 48 hours, Fig.
396 5d-f). Further studies will be required to determine the precise brain regions and structures that interact
397 with ABCLs, but the localization pattern observed is strikingly similar to that of fluorescein (a fluorescent
398 dye) after it is injected into the larval zebrafish ventricle [47]. Previous work in mammals has shown that
399 although the blood-brain barrier expresses the LDL-receptor, levels of ApoB within the cerebrospinal
400 fluid are extremely low [48]. These observations suggest that ABCLs may be preferentially retained in
401 the ventricle as a protected source of lipid for the brain in states of nutrient scarcity.
402 Although atherogenic lipoproteins are most often studied in the bloodstream as a means of
403 evaluating cardiovascular disease risk, these particles interact with essentially every tissue in the body
404 and are involved in numerous processes such as development [49], vision [50], angiogenesis [32],
405 heart function [51], hematopoiesis [52], infection and immunity [53, 54], cancer [55], and diabetes [56].
406 LipoGlo is an essential tool for broadening the scope of atherogenic lipoprotein biology beyond the
407 current focus on circulating particles. Although the vast majority of NanoLuc protein appears to be
408 associated with intact ABCLs, we cannot eliminate the possibility that some of the protein is cleaved
409 from the particle and may localize independently of ABCLs. Thus these preliminary observations
410 warrant further investigation and validation with orthogonal techniques.
411
412 **Characterization of lipoprotein abnormalities in *pla2g12b*$^{-/-}$ mutants**
413 Phospholipase A2 group XII B (Pla2g12b) is a catalytically inactive member of the
414 phospholipase gene family. Although this gene lacks catalytic activity and has no other known
415 function, its high level of evolutionary conservation suggests it may have evolved a new function.
416 Previous studies in mice have shown that disruption of *pla2g12b* results in decreased secretion of
417 hepatic triglyceride and ApoB [57], as well as reduced levels of HDL-cholesterol [58], indicating that
418 this gene may play a role in lipoprotein secretion. LipoGlo revealed that *pla2g12b*$^{-/-}$ mutant larvae

419 exhibited significantly lower levels of ApoB at multiple stages, and show enrichment of visceral
420 ApoB-NanoLuc levels, both of which are consistent with previously reported defects in lipoprotein
421 secretion. However, evaluation of the lipoprotein size distribution in *pla2g12b*$^{-/-}$ mutants revealed bias
422 towards production of small LDL-like particles, which has not been reported previously. Further
423 investigation will be required to determine whether smaller ABCLs are produced directly by the
424 YSL/liver, or if the decreased ABCL secretion rate results in rapid lipolysis of the few lipoproteins that
425 are successfully secreted. As Pla2g12b modulates both lipoprotein size and number, variants in this
426 gene may modulate risk for cardiovascular disease. Ongoing work is exploring both the mechanism of
427 action of this poorly understood protein, as well as the greater physiological repercussions of this
428 mutation.
429
430 **Overview of present and future application of LipoGlo**
431 Overall, this study provides several key insights. Firstly, covalent tags to ApoB enable highly
432 sensitive and specific monitoring of ABCLs without disrupting lipoprotein homeostasis. Secondly, the
433 larval zebrafish represents a powerful new model to study ABCLs, as developmental stages provide a
434 highly reproducible pattern of nutrient availability that shows human-like responses to genetic, dietary,
435 and pharmacological stimuli. Additionally, larval zebrafish have unparalleled tractability for genetic and
436 small-molecule screening as well as whole-organism imaging, facilitating the application of these
437 powerful discovery techniques to the field of lipoprotein biology. ABCLs also show significant patterns
438 of enrichment outside of the circulatory system (in association with the somite junctions and central
439 nervous system), laying the foundation for the continued study of extravascular ABCLs. Lastly,
440 *pla2g12b* is a highly conserved regulator of lipoprotein biogenesis that plays a central role in the
441 regulation of the lipoprotein size/subclass distribution. The LipoGlo system thus represents an essential
442 tool to expand our understanding of atherogenic lipoproteins and accelerate the discovery of new
443 approaches to combat atherosclerotic cardiovascular disease.
444
445
446

447 **ACKNOWLEDGEMENTS:**

448

449 We would like to thank Promega Corp. for providing the NanoLuc plasmid, as well as sample
450 reagents and technical advice that were essential to assay development, as well as serving as a co-
451 sponsor for a local lipid research conference where this work was presented. We would also like to
452 thank Michael Sepanski for collecting the electron micrographs, Dr. Marnie Halpern for providing the
453 unpublished *Tg(Xla.Tubb2:mapple-CAAX*) pan-neuronal marker line and valuable advice on the
454 manuscript, Dr. Yury Miller for providing the *apoC2* mutant line, and the Sanger Institute Zebrafish
455 Mutation project for providing the *pla2g12b* mutant line (sa659). Support was also provided by the
456 National Institutes of Health (R01DK093399 [S.A.F.] and R01DK116079 [S.A.F.]), National Heart, Lung,
457 and Blood Institute (F31HL139338 [J.H.T]) and National Institute of General Medical Sciences
458 (R01GM63904 [S.C.E] & [S.A.F] and P30DK084567 [S.C.E.]). This content is solely the responsibility of
459 the authors and does not necessarily represent the official views of NIH. Additional support for this work
460 was provided by the Carnegie Institution for Science endowment and the G. Harold and Leila Y.
461 Mathers Charitable Foundation (S.A.F).

462

463 **AUTHOR CONTRIBUTIONS:**

464 J.H.T. and S.A.F. conceived and designed the project, and met frequently to discuss results, plan
465 experiments, and troubleshoot protocols. S.C.E. provided critical reagents and expertise to design and
466 synthesize the TALENs used to create the LipoGlo fish line. J.H.T. executed the experiments, analyzed
467 the results, and wrote the original draft of the paper. J.H.T., S.C.E. and S.A F. revised, edited, and
468 approved the final submitted version of the manuscript.

469 .

470

471 **DECLARATION OF INTERESTS:**

472 The Authors declare no competing interests.

473

474

475 **REFERENCES:**

476

477 1. Tabas, I., K.J. Williams, and J. Boren, *Subendothelial lipoprotein retention as the initiating*
478 *process in atherosclerosis: update and therapeutic implications.* Circulation, 2007. **116**(16):
479 p. 1832-44.

480 2. WHO. *The top 10 causes of death*. Fact Sheets [Web Page] 2018 05/24/2018 [cited 2018
481 09/25/2018]; Available from: http://www.who.int/news-room/fact-sheets/detail/the-
482 top-10-causes-of-death.

483 3. Stone, N.J., et al., *2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce*
484 *atherosclerotic cardiovascular risk in adults: a report of the American College of*
485 *Cardiology/American Heart Association Task Force on Practice Guidelines.* Circulation, 2014.
486 **129**(25 Suppl 2): p. S1-45.

487 4. McQueen, M.J., et al., *Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial*
488 *infarction in 52 countries (the INTERHEART study): a case-control study.* Lancet, 2008.
489 **372**(9634): p. 224-33.

490 5. Sniderman, A.D., et al., *Discordance analysis of apolipoprotein B and non-high density*
491 *lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study.*
492 Atherosclerosis, 2012. **225**(2): p. 444-9.

493 6. Lawler, P.R., et al., *Atherogenic Lipoprotein Determinants of Cardiovascular Disease and*
494 *Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol.* J Am Heart
495 Assoc, 2017. **6**(7).

496 7. Rizzo, M. and K. Berneis, *Low-density lipoprotein size and cardiovascular risk assessment.*
497 QJM, 2006. **99**(1): p. 1-14.

498 8. Austin, M.A., et al., *Low-density lipoprotein subclass patterns and risk of myocardial*
499 *infarction.* JAMA, 1988. **260**(13): p. 1917-21.

500 9. Shim, H., et al., *A multivariate genome-wide association analysis of 10 LDL subfractions, and*
501 *their response to statin treatment, in 1868 Caucasians.* PLoS One, 2015. **10**(4): p. e0120758.
502 10. Chasman, D.I., et al., *Forty-three loci associated with plasma lipoprotein size, concentration,*
503 *and cholesterol content in genome-wide analysis.* PLoS Genet, 2009. **5**(11): p. e1000730.
504 11. Berneis, K.K. and R.M. Krauss, *Metabolic origins and clinical significance of LDL*
505 *heterogeneity.* J Lipid Res, 2002. **43**(9): p. 1363-79.
506 12. Rajman, I., et al., *LDL particle size: an important drug target?* Br J Clin Pharmacol, 1999.
507 **48**(2): p. 125-33.
508 13. Jacobson, T.A., *Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential*
509 *risk factors and treatment targets to reduce cardiovascular risk.* Mayo Clin Proc, 2011.
510 **86**(8): p. 762-80.
511 14. Xiao, C., et al., *Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next*
512 *Frontier in CVD Prevention Beyond Lowering LDL Cholesterol.* Diabetes, 2016. **65**(7): p.
513 1767-78.
514 15. Liu, C., et al., *Apoc2 loss-of-function zebrafish mutant as a genetic model of hyperlipidemia.*
515 Dis Model Mech, 2015. **8**(8): p. 989-98.
516 16. Schlegel, A., *Zebrafish Models for Dyslipidemia and Atherosclerosis Research.* Front
517 Endocrinol (Lausanne), 2016. **7**: p. 159.
518 17. O'Hare, E.A., et al., *Disruption of ldlr causes increased LDL-c and vascular lipid accumulation*
519 *in a zebrafish model of hypercholesterolemia.* J Lipid Res, 2014. **55**(11): p. 2242-53.
520 18. Mahley, R.W., *Central Nervous System Lipoproteins: ApoE and Regulation of Cholesterol*
521 *Metabolism.* Arterioscler Thromb Vasc Biol, 2016. **36**(7): p. 1305-15.
522 19. Rouault, M., et al., *Novel mammalian group XII secreted phospholipase A2 lacking enzymatic*
523 *activity.* Biochemistry, 2003. **42**(39): p. 11494-503.
524 20. Elovson, J., et al., *Plasma very low density lipoproteins contain a single molecule of*
525 *apolipoprotein B.* J Lipid Res, 1988. **29**(11): p. 1461-73.

526 21. Fisher, E., E. Lake, and R.S. McLeod, *Apolipoprotein B100 quality control and the regulation*
527 *of hepatic very low density lipoprotein secretion.* J Biomed Res, 2014. **28**(3): p. 178-93.
528 22. Kane, J.P., D.A. Hardman, and H.E. Paulus, *Heterogeneity of apolipoprotein B: isolation of a*
529 *new species from human chylomicrons.* Proc Natl Acad Sci U S A, 1980. **77**(5): p. 2465-9.
530 23. Davidson, N.O. and G.S. Shelness, *APOLIPOPROTEIN B: mRNA editing, lipoprotein assembly,*
531 *and presecretory degradation.* Annu Rev Nutr, 2000. **20**: p. 169-93.
532 24. Otis, J.P., et al., *Zebrafish as a model for apolipoprotein biology: comprehensive expression*
533 *analysis and a role for ApoA-IV in regulating food intake.* Dis Model Mech, 2015. **8**(3): p. 295-
534 309.
535 25. Hussain, M.M., et al., *Amino acids 430-570 in apolipoprotein B are critical for its binding to*
536 *microsomal triglyceride transfer protein.* J Biol Chem, 1998. **273**(40): p. 25612-5.
537 26. Boren, J., et al., *The molecular mechanism for the genetic disorder familial defective*
538 *apolipoprotein B100.* J Biol Chem, 2001. **276**(12): p. 9214-8.
539 27. Hall, M.P., et al., *Engineered luciferase reporter from a deep sea shrimp utilizing a novel*
540 *imidazopyrazinone substrate.* ACS Chem Biol, 2012. **7**(11): p. 1848-57.
541 28. Shin, J., J. Chen, and L. Solnica-Krezel, *Efficient homologous recombination-mediated genome*
542 *engineering in zebrafish using TALE nucleases.* Development, 2014. **141**(19): p. 3807-18.
543 29. Miyares, R.L., V.B. de Rezende, and S.A. Farber, *Zebrafish yolk lipid processing: a tractable*
544 *tool for the study of vertebrate lipid transport and metabolism.* Dis Model Mech, 2014. **7**(7):
545 p. 915-27.
546 30. Hussain, M.M., J. Shi, and P. Dreizen, *Microsomal triglyceride transfer protein and its role in*
547 *apoB-lipoprotein assembly.* J Lipid Res, 2003. **44**(1): p. 22-32.
548 31. Jong, M.C., M.H. Hofker, and L.M. Havekes, *Role of ApoCs in lipoprotein metabolism:*
549 *functional differences between ApoC1, ApoC2, and ApoC3.* Arterioscler Thromb Vasc Biol,
550 1999. **19**(3): p. 472-84.

551 32. Avraham-Davidi, I., et al., *ApoB-containing lipoproteins regulate angiogenesis by modulating*
552 *expression of VEGF receptor 1.* Nat Med, 2012. **18**(6): p. 967-73.
553 33. Cuchel, M., et al., *Inhibition of microsomal triglyceride transfer protein in familial*
554 *hypercholesterolemia.* N Engl J Med, 2007. **356**(2): p. 148-56.
555 34. Carten, J.D., M.K. Bradford, and S.A. Farber, *Visualizing digestive organ morphology and*
556 *function using differential fatty acid metabolism in live zebrafish.* Dev Biol, 2011. **360**(2): p.
557 276-85.
558 35. Feingold, K.R. and C. Grunfeld, *Introduction to Lipids and Lipoproteins*, in *Endotext*, L.J. De
559 Groot, et al., Editors. 2000: South Dartmouth (MA).
560 36. Singh, Y., et al., *A rapid 3% polyacrylamide slab gel electrophoresis method for high through*
561 *put screening of LDL phenotype.* Lipids Health Dis, 2008. **7**: p. 47.
562 37. Hoefner, D.M., et al., *Development of a rapid, quantitative method for LDL subfractionation*
563 *with use of the Quantimetrix Lipoprint LDL System.* Clin Chem, 2001. **47**(2): p. 266-74.
564 38. Sato, A., et al., *Angiotensin II induces the aggregation of native and oxidized low-density*
565 *lipoprotein.* Eur Biophys J, 2018. **47**(1): p. 1-9.
566 39. Tiwari, S. and S.A. Siddiqi, *Intracellular trafficking and secretion of VLDL.* Arterioscler
567 Thromb Vasc Biol, 2012. **32**(5): p. 1079-86.
568 40. Yee, M.S., et al., *Lipoprotein separation in a novel iodixanol density gradient, for composition,*
569 *density, and phenotype analysis.* J Lipid Res, 2008. **49**(6): p. 1364-71.
570 41. Garewal, M., L. Zhang, and G. Ren, *Optimized negative-staining protocol for examining lipid-*
571 *protein interactions by electron microscopy.* Methods Mol Biol, 2013. **974**: p. 111-8.
572 42. Westerfield, M., *The zebrafish book: a guide for the laboratory use of zebrafish (Danio rerio)*.
573 2007: University of Oregon press.
574 43. Kettleborough, R.N., et al., *A systematic genome-wide analysis of zebrafish protein-coding*
575 *gene function.* Nature, 2013. **496**(7446): p. 494-7.

576 44. Chico, T.J., P.W. Ingham, and D.C. Crossman, *Modeling cardiovascular disease in the*
577 *zebrafish.* Trends Cardiovasc Med, 2008. **18**(4): p. 150-5.
578 45. Charvet, B., et al., *Development of the zebrafish myoseptum with emphasis on the*
579 *myotendinous junction.* Cell Tissue Res, 2011. **346**(3): p. 439-49.
580 46. Tsouli, S.G., et al., *Regression of Achilles tendon thickness after statin treatment in patients*
581 *with familial hypercholesterolemia: an ultrasonographic study.* Atherosclerosis, 2009.
582 **205**(1): p. 151-5.
583 47. Henson, H.E., et al., *Functional and genetic analysis of choroid plexus development in*
584 *zebrafish.* Front Neurosci, 2014. **8**: p. 364.
585 48. Dehouck, B., et al., *A new function for the LDL receptor: transcytosis of LDL across the blood-*
586 *brain barrier.* J Cell Biol, 1997. **138**(4): p. 877-89.
587 49. Neumann, S., et al., *Mammalian Wnt3a is released on lipoprotein particles.* Traffic, 2009.
588 **10**(3): p. 334-43.
589 50. Pikuleva, I.A. and C.A. Curcio, *Cholesterol in the retina: the best is yet to come.* Prog Retin Eye
590 Res, 2014. **41**: p. 64-89.
591 51. Yu, X., et al., *Inhibition of cardiac lipoprotein utilization by transgenic overexpression of*
592 *Angptl4 in the heart.* Proc Natl Acad Sci U S A, 2005. **102**(5): p. 1767-72.
593 52. Liu, C., et al., *Lipoprotein lipase regulates hematopoietic stem progenitor cell maintenance*
594 *through DHA supply.* Nat Commun, 2018. **9**(1): p. 1310.
595 53. Manifold-Wheeler, B.C., et al., *Serum Lipoproteins Are Critical for Pulmonary Innate Defense*
596 *against Staphylococcus aureus Quorum Sensing.* J Immunol, 2016. **196**(1): p. 328-35.
597 54. Bashmakov, Y.K., et al., *ApoB-containing lipoproteins promote infectivity of chlamydial*
598 *species in human hepatoma cell line.* World J Hepatol, 2010. **2**(2): p. 74-80.
599 55. Borgquist, S., et al., *Apolipoproteins, lipids and risk of cancer.* Int J Cancer, 2016. **138**(11): p.
600 2648-56.

601 56. Ley, S.H., et al., *Association of apolipoprotein B with incident type 2 diabetes in an aboriginal*
602 *Canadian population.* Clin Chem, 2010. **56**(4): p. 666-70.
603 57. Guan, M., et al., *Hepatocyte nuclear factor-4 alpha regulates liver triglyceride metabolism in*
604 *part through secreted phospholipase A(2) GXIIB.* Hepatology, 2011. **53**(2): p. 458-66.
605 58. Aljakna, A., et al., *Pla2g12b and Hpn are genes identified by mouse ENU mutagenesis that*
606 *affect HDL cholesterol.* PLoS One, 2012. **7**(8): p. e43139.
607 59. Neff, K.L., et al., *Mojo Hand, a TALEN design tool for genome editing applications.* BMC
608 Bioinformatics, 2013. **14**: p. 1.
609 60. Ma, A.C., et al., *FusX: A Rapid One-Step Transcription Activator-Like Effector Assembly System*
610 *for Genome Science.* Hum Gene Ther, 2016. **27**(6): p. 451-63.
611 61. Petersen, L.K. and R.S. Stowers, *A Gateway MultiSite recombination cloning toolkit.* PLoS
612 One, 2011. **6**(9): p. e24531.
613 62. Rumsey, S.C., et al., *Cryopreservation with sucrose maintains normal physical and biological*
614 *properties of human plasma low density lipoproteins.* J Lipid Res, 1992. **33**(10): p. 1551-61.
615 63. Meeker, N.D., et al., *Method for isolation of PCR-ready genomic DNA from zebrafish tissues.*
616 Biotechniques, 2007. **43**(5): p. 610, 612, 614.
617
618
619
620 **MATERIALS AND METHODS:**
621
622 **Zebrafish husbandry and maintenance**
623 Adult zebrafish were maintained on a 14 h light – 10 h dark cycle and fed once daily with ~3.5%
624 body weight of Gemma Micro 500 (Skretting USA). All genotypes were bred into the wild-type AB
625 background. All assays were performed on larvae heterozygous for the ApoB-Nanoluc reporter unless
626 otherwise noted. To monitor the wild-type lipoprotein profile throughout larval development, pairwise
627 crosses were set up between wild-type AB adults and adults homozygous for the ApoB-NanoLuc

628 reporter (*apoBb.1*$^{NLuc/NLuc}$). To characterize the lipoprotein profile of *mtp* mutant larvae [32], pairwise
629 crosses were set up between *mtp*$^{stl/+}$ and *mtp*$^{stl/+}$; *apoBb.1*$^{NLuc/NLuc}$ adults. To characterize the lipoprotein
630 profile of *apoC2* mutant larvae [15], pairwise crosses were set up between *apoC2*$^{sd38/sd38}$ and
631 *apoC2*$^{sd38/+}$; *apoBb.1*$^{NLuc/+}$ adults and larvae positive for the NanoLuc reporter were selected for
632 analysis. To characterize the lipoprotein profile of *pla2g12b* mutant larvae [43], pairwise crosses were
633 set up between *pla2g12b*$^{sa659/sa659}$ and *pla2g12b*$^{sa659/+}$; *apoBb.1*$^{NLuc/+}$ adults. To evaluate association
634 between the ABCLs and the central nervous system, adults homozygous for the ApoB-NanoLuc
635 reporter (*apoBb.1*$^{NLuc/NLuc}$) were crossed to adults heterozygous for the central nervous system marker
636 *Tg(Xla.Tubb2:mapple-CAAX)*, and embryos were screened for mApple prior to fixation and mounting
637 (unpublished reagent provided by the Halpern Lab, c583). As zebrafish sex cannot be determined
638 during the larval stages, gender can be excluded as a variable. All procedures were approved by the
639 Carnegie Institution Animal Care and Use Committee (Protocol #139).
640
641 **Genome editing**
642 Genome integration was achieved by co-injection of 500 pg of TALEN mRNA and 30 pg of
643 donor plasmid into 1-cell stage embryos (Supplementary Fig. 2a). Two pairs of TALENs were designed
644 and cloned that target a BsrI restriction site just upstream of the endogenous stop codon of ApoBb.1
645 using the Mojo Hand design tool [59] and FusX assembly system [60]. TALENs were *in-vitro*
646 transcribed using the T3 mMessage mMachine kti (ThermoFisher Scientific, AM1348) and injected into
647 1-cell stage zebrafish embryos. Cutting efficiency was quantified by monitoring the loss of BsrI
648 digestion as a result of TALEN nuclease activity, and found to be significantly higher in TALEN pair 2,
649 so this pair was used for genome integration efforts (Supplementary Fig. 2b). A donor plasmid was
650 cloned using 3-fragment MultiSite gateway assembly (Invitrogen, 12537-023) with a 5' entry element of
651 ~500 bp of the genomic sequence upstream of the ApoBb.1 stop codon, a middle-entry element
652 consisting of in-frame NanoLuc coding sequence, and a 3' element of ~700 bp of genomic sequence
653 downstream of the ApoBb.1 stop codon [61]. Injected embryos were raised to adulthood and progeny
654 were screened for NanoLuc activity and in-frame fusion of the NanoLuc reporter at the target locus
655 (Supplementary Fig. 2c).

656

657 **Preparation and storage of larval homogenate**

658 Individual larvae are homogenized in a standard volume of ABCL stabilization buffer (100 μL).
659 The ABCL stabilization buffer (see recipes) contains cOmplete Mini, EDTA-free Protease Inhibitor
660 Cocktail (Millipore-Sigma, 11836170001), pH buffer and calcium chelator (EGTA, pH 8), and
661 cryoprotectant [62] (Sucrose) to preserve sample integrity during homogenization (Supplementary Fig.
662 6). The buffer is made as a 2x stock, and larvae are anesthetized in tricaine and placed into tubes in a
663 50 μL volume and an equal volume of chilled 2x buffer is then added just prior to homogenization. Low-
664 throughput homogenization can be achieved in 1.5 mL centrifuge tubes with disposable pellet-pestles
665 (Fisher scientific, 12-141-363). For high-throughput sample processing, larvae and ABCL stabilization
666 buffer are dispensed into individual wells of a 96-well non-skirted PCR-plate (USAScientific, #1402-
667 9589), sealed with microSeal 'B' plate sealing film (Bio-Rad, msb1001), and homogenized in a
668 microplate-horn sonicator (Qsonica, Q700 sonicator with 431MPX microplate horn assembly). For
669 sonication, the plate was placed in the microplate horn filled with 17 mm of chilled RO water and
670 processed at 100% power for a total of 30 seconds, delivered as 2-second pulses interspersed with 1-
671 second pauses. Homogenate was stored on ice for immediate use, or frozen at -20° C and thawed on
672 ice for later use.

673

674 **Quantification of ApoB-NanoLuc levels using a plate reader**

675 To quantify ApoB-NanoLuc levels, homogenate (40 μL) was mixed with an equal volume of
676 diluted NanoLuc buffer (for specific dilution see recipes and technical note on NanoLuc buffer) in a 96-
677 well opaque white OptiPlate (Perkin-Elmer, 6005290). Black plates can be used as an alternative that
678 will significantly lower absolute signal intensity, but also reduce light contamination into adjacent wells.
679 The plate was read within 2 minutes of buffer addition using a SpectraMax M5 plate reader
680 (Moleculardevices) set to top-read chemiluminescent detection with a 500 ms integration time. This
681 plate-based assay has a wide linear range and long half-life (Supplementary Fig. 7a-c). However,
682 degree of pigmentation has a significant effect on signal intensity, so this variable should be accounted

683 for with a standard curve or pigment-matched controls should be used as a baseline for comparison
684 (Supplementary Fig. 7d).
685
686
687 **Quantification of lipoprotein size distribution with LipoGlo-electrophoresis**
688 To quantify the electrophoretic mobility of ABCLs, 3% native polyacrylamide gels were cast in
689 Bio-rad mini-protean casting rigs using 1 mm spacer plates and 10-well combs (see recipes). Gels were
690 allowed to polymerize overnight at 4°C and used within 24 h of casting. Each gel included a migration
691 standard comprised of Di-I labeled human LDL (L3482, ThermoFisher Scientific) that was diluted in
692 cryoprotectant and stored in frozen aliquots (see recipes). Gels were assembled into mini-protean
693 electrophoresis rigs at 4°C, filled with pre-chilled 1x TBE and pre-run at 50 V for 30 minutes to
694 equilibrate the gel prior to sample addition. 12 μL of homogenate was then combined with 3 μL of 5x
695 load dye (see recipes), and 12.5 μL of the resulting solution was loaded per well (which corresponds to
696 10% of the larval homogenate per lane). Gels were then run at 50 V for 30 minutes, followed by 125
697 volts for 2 h.
698 Gels were imaged within 1 h of completion of the run. To image each gel, the thin glass short
699 plate was carefully separated from the front of the gel with a gel releaser wedge (see technical note on
700 hydrophobic coating of short plates). With the gel resting on the thick spacer plate, 1 mL of TBE
701 supplemented with 2 μL of Nano-Glo substrate was gently pipetted onto the gel surface. The gel
702 imaging solution was spread evenly across the gel surface with a thin plastic film cut to the size of the
703 spacer plate (Staples, Sliding bar report covers). After a 5-minute equilibration, the gel was placed into
704 an Odyssey Fc (LI-COR Biosciences) gel imaging system (See technical note on gel imaging) and
705 imaged in the chemiluminescence channel for 2 minutes (NanoLuc detection) and then the 600 channel
706 for 30 seconds (Di-I LDL standard detection). Raw images were exported as zip files for further
707 analysis.
708 The provided gel quantification template (Supplemental File 1) can be used to bin the complex
709 lipoprotein size distribution into biologically relevant groups for analysis, and detailed instructions are
710 provided within the supplemental file. In short, each lane was converted to a plot profile in ImageJ, and

711 divided into LDL, IDL, VLDL, and ZM bins based on migration relative to the Di-I standard, and pixel
712 intensity was summed within each bin for analysis.
713
714
715 **Larvae fixation and imaging**
716 To determine the whole-organism localization of ABCLs, intact larvae are anesthetized and
717 fixed in 4% PFA (diluted in PBS) for 3 h at room temperature. Following fixation, larvae are rinsed 3
718 times for 15 minutes each in PBS-tween (PBS containing 0.1% tween-20 detergent) and imaged within
719 12 h of fixation. Agarose for mounting is prepared by melting 0.1 grams of low-melting point agarose
720 (BP160-100, Fisher Scientific) in 10 mLs of 1x TBE. Aliquots are maintained in the liquid state at 42°C
721 in a heat block. Just prior to mounting, agarose aliquots were supplemented with 1% Nano-Glo
722 substrate (furimazine). Fixed larvae are arrayed in droplets on a petri dish lid, and the excess liquid is
723 removed and quickly replaced with a 50 μL droplet of low-melt agarose containing Nano-Glo substrate
724 (1%). The sample is then oriented properly with a flexible poker until the agarose solidifies sufficiently to
725 hold the sample in place. This process was repeated for up to 15 larvae in parallel prior to imaging.
726 To image the ABCL localization, a Zeiss Axiozoom V16 microscope V16 equipped with a Zeiss
727 AxioCam MRm was set to 30x magnification, 2x2 binning and 2x gain (to increase sensitivity), and
728 programmed to collect a single brightfield exposure (2.4 ms, 10% light intensity) followed by two
729 chemiluminescent imaging exposures (10 and 30 seconds, respectively) with no illumination to collect
730 the NanoLuc signal (See technical note on NanoLuc imaging). Images were quantified in ImageJ by
731 using the brightfield exposure to draw regions of interest (viscera, trunk, and head) and calculating the
732 NanoLuc intensity within each of those ROIs for 30 second chemiluminescent exposure, unless
733 saturated pixels were detected in which case the 10 second exposure was used.
734
735 **Density-gradient ultracentrifugation**
736 A density gradient ultracentrifugation (DGUC) protocol was developed by adapting previously
737 published protocols using a 3-layer iodixanol gradient to function with smaller volumes of input sample
738 [40]. Individual larvae were sonicated in 100 μL of sucrose-free ABCL buffer (see recipes) to avoid

739 disruption of the density gradient with sucrose. 15 larvae were pooled per experiment into a single 1.5
740 mL centrifuge tube and centrifuged for 5 minutes at 6,000 rcf to remove large cellular debris. 1 mL of
741 the resulting supernatant was transferred to a separate tube containing 500 μL of Optiprep Density
742 gradient medium (D1556, Sigma-Aldrich) to yield a 20% iodixanol solution. A 9% iodizanol solution was
743 prepared by adding 1.5 mL of Optiprep to a 15 mL conical tube containing 8.5 mL HEPES-buffered
744 saline (HBS, see recipes), and a 12% solution was prepared by mixing 2 mL Optiprep with 8 mL HBS.
745 A 4.9 mL Optiseal tube (formerly polyallomer, 362185, Beckman-Coulter) was then loaded with 1.5 mL
746 of 9% iodixanol/HBS solution. This solution was carefully underlayered with 1.5 mL of the 12%
747 iodixanol solution using a p1000 pipette fit with both the appropriate p1000 tip as well as a tapered gel
748 loading tip which functioned as a disposable plastic cannula (USA Scientific, 1252-0610). Finally, these
749 solutions were underlayered with 1.5 mL of the 20% iodixanol solution containing the zebrafish
750 homogenate. The tube was then topped up with HBS (~500 uL) so that no air remained and sealed with
751 a cap. Balanced tubes were then loaded into a VTi65.2 rotor and centrifuged at 60,000 rpm in a
752 prechilled Beckman Optima XL 80K Ultracentrifuge set to 4°C with maximum acceleration and
753 deceleration rates.

754 Following ultracentrifugation, density fractions were collected by carefully piercing the bottom of
755 the tube with a thumbtack, and drip-eluting the samples into 10 separate fractions of approximately 500
756 μL each. The refractive index of each fraction was determined using a Bausch and Lomb refractometer,
757 and used to calculate solution density using the formula density = 3.3508 x (refractive index) - 3.4675.
758 Fractions were stored on ice or at 10°C, and used within 24 h for a plate-based NanoLuc assay,
759 LipoGlo-electrophoresis, and negative-staining electron microscopy. Note that the high protein and
760 iodixanol content of fraction 1 (highest density) introduces artifacts in the native gel and was therefore
761 excluded, which allowed lane 1 to be dedicated to the Di-I LDL standard.

762

763 **Negative-staining electron microscopy**

764 Fractions 4, 7, and 10 from the DGUC experiments outlined above were subjected to negative-
765 staining electron microscopy [41]. 300-mesh copper grids coated with 10 nm formvar and 1 nm carbon
766 (Electron Microscopy Sciences, FCF300-Cu) were ionized using the glow discharge filament in a

767 Denton Vacuum dv-502 evaporator at 75 mTorr for 30 seconds. Anti-capillary forceps were then used
768 to hold the grids in a humidified chamber, and 3 μL of the sample was carefully placed on the surface of
769 the grid and incubated at room temperature for 10 minutes to allow the lipoproteins to adhere to the
770 grid. The grid was then rinsed in 5 droplets of RO-water and then finally 2 droplets of 2% uranyl
771 acetate, and touched lightly to a piece of filter paper to remove excess stain. Grids were imaged at
772 26,000x magnification on a Tecnai 12 transmission electron microscope.
773
774 **DNA extraction and Genotyping**
775 Sonication of zebrafish larvae is a convenient method for highly-parallelized homogenization, as
776 a full plate (96 samples) can be processed simultaneously. However, this process shears DNA into
777 significantly smaller fragments, meaning longer amplicons will amplify less efficiently or not at all. To
778 circumvent this issue, genotyping protocols for this study were designed to use small amplicons (less
779 than 350 bp). If intact DNA is needed for downstream applications, the pellet-pestle method can be
780 used interchangeably with sonication.
781 DNA extraction of larval homogenate can be achieved with a modified version of the HotShot
782 DNA extraction protocol [63]. 10 μL homogenate is transferred to a pcr tube/plate containing 10 μL of
783 100 mM NaOH, and heated at 95°C for 20 minutes. The solution was then neutralized with an equal
784 volume (20 μL) of 100 mM Tris pH 8, and either stored frozen (-20 °C)or used immediately as a
785 template for genotyping PCR (2 μL per reaction).
786 Genotyping was carried out using gene-specific primers (Supplementary Table 1). The
787 ApoBb.1-NanoLuc locus was genotyped using 3 primers with final concentrations as follows: 1μM
788 primer 9, .2μM primer 10, and .8μM primer 11. This ratio provides similar band intensity for the 113
789 bp product indicating presence of the WT allele, and the 161 bp product indicating NanoLuc fusion
790 allele (T_a = 57°C, extension time 20'') in heterozygotes (only one band will amplify in homozygotes).
791 The *mtp* genotyping locus was amplified using primers 12 and 13 (.5μM each, T_a = 60°C, extension
792 time 30''), and digested with 3 units of AvaII restriction enzyme, which cuts the mutant (*stll)* allele. Wild-
793 type zebrafish should have a single 157 bp band, homozygous mutants should have a shorter 129 bp
794 band, and heterozygotes should have both bands present (note the 28 bp fragment is not usually

795 detectable). The *apoC2* genotyping locus was amplified using primers 14 and 15 (.5μM each, T_a =
796 57°C, extension time 30''), and digested with 3 units of BtsαI restriction enzyme, which cuts the WT
797 allele but not the sd38 mutant allele. Wild-type zebrafish should have 102 and 45 bp bands,
798 homozygous mutants should have a single 147 bp band, and heterozygotes should have all 3 bands
799 present. The *pla2g12b* genotyping locus was amplified using primers 16 and 17 (.5μM each, T_a = 57°C,
800 extension time 30''), and digested with 3 units of BtsαI restriction enzyme, which cuts the mutant
801 (sa659) allele. Wild-type zebrafish should have a single 150 bp band, homozygous mutants should
802 have a shorter 111 bp band, and heterozygotes should have both bands present (note the 39 bp
803 fragment is not usually detectable).
804
805 **Technical notes and troubleshooting**
806
807 NanoLuc Buffer
808 The NanoLuc enzyme is active in various buffers, but the key consideration is to ensure that
809 substrate is in excess. Manufacturer's instructions dictate that 1 mL of Buffer plus 20 μL of substrate
810 solution constitutes a 2x buffer, but we have found that this 2x buffer can be diluted 4-fold in PBS and
811 the substrate remains in significant excess.
812
813 Hydrophobic coating of LipoGlo-electrophoresis plates
814 The most likely source of artifacts in the LipoGlo-electrophoresis protocol are from stretching or
815 distortion of the fragile 3% polyacrylamide gel while removing the short plate from the gel. To
816 circumvent this issue, the short plates were coated on both sides with Rain-X original glass water
817 repellent (Rain-X, 3.5 oz. bottle). This hydrophobic coating greatly facilitates removal of the short plate
818 while leaving the undistorted gel resting on the spacer plate. This coating is semi-permanent, so it is
819 recommended that a set of coated short plates be dedicated for this purpose and reapplied with coating
820 as needed.
821 This hydrophobic coating also reduces friction between the short plate and the spacer plate, so
822 it is important that the plates are aligned properly in the casting frames and placed very gently in the

823 casting stands. Too much pressure from the casting stand can cause the plates to slide out of
824 alignment and lead to leaking during casting.
825
826 Imaging of LipoGlo-electrophoresis gels
827 The Odyssey Fc offers sensitive signal detection as well as multi-color detection, and is
828 therefore ideal for imaging lipoprotein gels. However, if this equipment is not available, alternative gel
829 imaging systems or a sensitive camera are capable of imaging the gel as well, as the chemiluminescent
830 signal should be detectable by essentially any detector although the exposure time may need to be
831 increased to the order of minutes depending on the sensitivity of the detector. If simultaneous imaging
832 in chemiluminescent and fluorescent channels is not available, a large aliquot of zebrafish homogenate
833 (such as 6 dpf larvae) can be pooled, aliquoted, frozen, and used as an alternative migration
834 normalization standard.
835
836 NanoLuc imaging
837 Essentially all background signal in this imaging paradigm comes from two sources: electrical
838 noise from the camera, and light contamination from the environment. Camera noise can be attenuated
839 by using an actively cooled camera and by enabling a blank-subtraction setting to eliminate hot pixels.
840 To reduce contaminating light from the environment, we recommend collecting images in a dark room
841 and shrouding the stage and/or microscope to prevent light from reaching the imaging path.
842 Additionally, we have found that the Zeiss Axiozoom V16 contains infrared emitters and detectors
843 within the imaging path, which result in very high background when long exposures are used. To
844 overcome this issue, we placed a Zeiss BG40 IR blocking filter in front of the camera which effectively
845 filtered the contaminating infrared light.
846
847 **Solutions/Recipes**
848
849 ABCL Stabilization Buffer (2x): For routine preparation of zebrafish homogenate
850 1 CoMplete mini protease inhibitor tablet

851 400 μL .5M EGTA (pH8)

852 1g Sucrose

853 Adjust volume to 5 mL with reverse osmosis (RO) water

854

855 Sucrose-free ABCL Stabilization Buffer (2x): For preparation of zebrafish homogenate for

856 ultracentrifugation

857 1 CoMplete mini protease inhibitor tablet

858 400 μL .5M EGTA (pH8)

859 Adjust volume to 5 mL with RO water

860

861 Diluted NanoLuc Buffer (2x): For plate-based measurement of NanoLuc activity

862 1 mL Nano-Glo buffer

863 3 mL PBS

864 20 μL NanoLuc Substrate (furimazine solution)

865

866 3% Native Polyacrylamide gels (32 mL, ~4 mini gels): For LipoGlo-electrophoresis of ABCLs from larval

867 homogenate

868 22.9 mL RO water

869 6.4 mL 5x TBE

870 2.4 mL 40% 19:1 polyacrylamide:bis

871 →De-gas under vacuum for 30 minutes

872 250 μL 10% APS

873 20 μL TEMED

874 →quickly mix by gentle inversion and transfer to casting plates

875

876 Di-I LDL Lipoprotein migration standard: For normalization of electrophoretic mobility in Ladder Units

877 200 μL DiI LDL (L3482, Thermofisher Scientific)

878 4 mL 1x TBE

879 .48 g sucrose (for 10%)

880 Adjust final volume to 4.8 mL with TBE

881 →Divide into 50 μL aliquots and store at -80°C

882

883 5x loading dye: For loading homogenate into LipoGlo-electrophoresis gels

884 4 g sucrose

885 25 mg bromophenol blue

886 Adjust to 10 mL with TBE

887

888

889 Gel imaging solution (1 gel): For in-gel chemiluminescent imaging of NanoLuc

890 1 mL TBE

891 2 μL furimazine substrate

892

893 Mounting and Imaging solution (1 mL, ~20 larvae): For imaging of ABCL distribution in intact larvae

894 .1g low-melt agarose

895 10 mL 1x TBE

896 →heat in microwave (5-15 seconds) and swirl until dissolved

897 →Distribute to 1 mL aliquots in 42°C heat block

898 Add 10 μL furimazine to 1 mL liquid agarose just prior to mounting

899

900

901 HEPES-Buffered Saline: For establishing density gradient for ultracentrifugation

902 .85g NaCl

903 10 mL 1M HEPES buffer (pH 7.4)

904 90 mL RO water

905

906

907 **QUANTIFICATION AND STATISTICAL ANALYSIS**

908

909 All datasets were initially subjected to Levene's test for homogeneity of variance. For datasets
910 with a single factor and uniform variance, a one-way ANOVA was used to test for a main effect, and
911 Tukey's HSD was used for *post hoc* testing. If variance was not uniform (Levene's <.05), Welch's
912 ANOVA with a *post hoc* Games-Howell test was used as these tests are robust to the assumption of
913 unequal variance. For two-factor datasets, the Robust Two-Factor ANOVA was used with a *post hoc*
914 Games-Howell test. * denotes p<.01, ** denotes p<.001, and *** denotes p<.0001. For LipoGlo-
915 electrophoresis experiments, statistical tests were run independently for each of the four groups of
916 binned data (ZM, VLDL, IDL, and LDL). In this case, Bonferroni correction was used to adjust for
917 multiple comparisons (corrected significant p<.0125). Bonferroni correction was also applied to the
918 LipoGlo-Microscopy experiments which are binned into three groups, so a significant threshold was set
919 at p<.017. All statistics were run using XLSTAT, with the exception of the Robust Two-Factor ANOVA
920 which was executed in R using the pbad2way function in the WRS2 package (https://cran.r-
921 project.org/web/packages/WRS2/index.html).

922

923

924

925

926 **KEY RESOURCES TABLE**

927

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Critical Commercial Assays		
Nano-Glo assay	Promega Corp	N1110
Di-I-Labeled fluorescent LDL	ThermoFisher Scientific	L3482
Experimental Models: Organisms/Strains		
ApoB-NanoLuc fusion allele (*apoBb.1*^{NLuc})	Farber Lab (Carnegie)	ZIRC stock TBD

Mutant *mtp* allele (*mtp*^{stl})	Yaniv Lab (Weizmann)	ZIRC stock TBD
Mutant *apoC2* allele (*apoC2*^{sd38})	Miller Lab (UCSD)	ZIRC stock TBD
Mutant *pla2g12b* allele (*pla2g12b*^{sa659})	Sanger Institute	ZIRC stock TBD
CNS marker *Tg(Xla.Tubb2:mapple-CAAX)*	Halpern Lab (Carnegie)	ZIRC stock TBD
Recombinant DNA		
TALEN pair 1 – left arm	Farber Plasmid Stock 1512	Addgene stock TBD
TALEN pair 1 – right arm	Farber Plasmid Stock 1513	Addgene stock TBD
TALEN pair 2 – left arm	Farber Plasmid Stock 1514	Addgene stock TBD
TALEN pair 2 – right arm	Farber Plasmid Stock 1515	Addgene stock TBD
Donor plasmid with homology arms flanking NanoLuc coding sequence	Farber Plasmid Stock 1511	Addgene stock TBD

928

929

930

931

932



Supplementary Figure 1:
Conservation of functional domains in the zebrafish ApoBb.1 ortholog of Human APOB. (a) APOB has a penta-partite domain structure, with an amino-terminal globular domain followed by a series of beta and alpha domains. Consistent with other apolipoprotein sequences, APOB shows relatively low sequence conservation between species at the amino acid level (25% identical, 43% similar, green indicates >30% identity in identity plot). However, sequence conservation is enriched in known ApoB functional domains. For example, there is clear conservation of a signal peptide motif at the amino terminus. The MTP-interacting domain shows 39% identity and 63% similarity, and the LDL-R interacting motifs are also well-conserved. However, the ApoB-48 editing site appears completely absent, as zebrafish *apoBb.1* lacks the essential C6666 that is edited to form the premature stop, as well as the APOBEC mooring site, and shows only mild AT-richness that has been shown to be important for APOBEC binding **(b)** To further evaluate whether *apoB*-editing takes place in zebrafish, RNA reads were mapped back to this genomic locus. Post-transcriptional C→U editing would appear as a C→T polymorphism in the genomic sequence. 23 instances of C→T polymorphism were observed, but the vast majority (21) appeared in the wobble position (position 3) of the codon as would be expected for true polymorphisms (rather than post-transcriptional RNA-editing). Of the single instance that occurred in position 1, this did not result in a premature stop codon, providing further support for the absence of APOB-editing activity in zebrafish.



Supplementary Figure 2:
Introduction of an in-frame NanoLuc fusion protein at the endogenous *apoBb.1* locus. (a) A BsrI restriction site overlaps partially with the *apoBb.1* stop codon. Two independent pairs of TALENs were designed as shown, and **(b)** tested for cutting efficiency which was quantified as a loss of susceptibility to BsrI digest. TALEN pair 2 showed significantly higher cutting efficiency, and was selected for co-injection with the DNA donor construct (n=24, ANOVA p<0.0001, Tukey's HSD p<.0001). **(c)** An incross of adult fish heterozygous for the LipoGlo reporter revealed the expected mendelian ratio of offspring, and showed that homozygous carriers produce approximately twice the signal intensity as heterozygotes (1.2E7±1.3E6 vs 6.5E6±7.3E5) (n≈16, ANOVA p<0.0001, Tukey's HSD p<.0001). Heterozygous and homozygous carriers of the LipoGlo reporter are viable, fertile, and free of overt morphological defects.



Supplementary Figure 3:
Development of an effective migration standard for lipoprotein gels. It is essential that lipoprotein gels include a ladder or normalization standard that has similar electrophoretic properties to ABCLs. Di-I labeled human LDL serves as a commercially available option that enables standardization not only between multiple gels but also between different labs. **(a)** Di-I LDL was subjected to a series of 2-fold dilutions and separated via Native-PAGE as described and imaged with the Licor-Fc to determine an appropriate dilution factor that was still readily detectable. **(b)** Plot profiles of each of the serial dilutions revealed retardation of peak mobility in the highly concentrated samples, potentially due to overcrowding. Dilution factors between 16 and 32-fold were selected as acceptable (green box), and a 24-fold dilution was used for subsequent assays. **(c)** Sucrose was included as a cryoprotectant during Di-I LDL dilution, and there is no change in peak particle mobility across at least 3 freeze-thaw cycles in the presence of 10% sucrose, whereas the ladder is almost completely aggregated without cryoprotectant. **(d)** To determine the relationship between mobility of the standard and lipoprotein samples, homogenate was prepared and pooled from *mtp* -/- (3 dpf) mutant larvae (which produce primarily LDL-like particles). Samples of homogenate were run alongside Di-I standard for either 150, 212.5, 275, or 337.5 volt-hours, and the peak migration (in pixels) was quantified for each species. **(e)** While there was a clear linear relationship between ABCL migration and voltage applied (R^2=.95), **(f)** the relationship was much tighter when electrophoretic mobility was compared to the migration standard (R^2=.99), validating the utility of Di-I LDL as a migration standard.



Supplementary Figure 4:
Side-by-side analysis of LipoGlo-Electrophoresis and Microscopy results from mutant genotypes. (a) Plots of electrophoresis and **(b)** microscopy data reported in the main text grouped by subclass rather than by genotype and showing standard deviations.



Supplementary Figure 5:
LipoGlo microscopy reveals ABCL localization. (a) Three independent clutches of larvae carrying both the CNS marker *Tg(Xla. Tubb2-mApple-CAAX)* and ApoB-NanoLuc fusion were fixed and imaged at 4, 5, and 6 dpf as described in the methods section. A 20x100 pixel region of interest (ROI) was drawn centered around the spinal cord (marked by mApple) just distal to the intestine. The mApple and ApoB-NanoLuc channels are displayed separately below (representative of 15 images per time point). **(b)** Quantification of the signal intensity in spinal cord (CNS) versus peripheral regions revealed a gradual enrichment of signal in the CNS relative to the periphery from 4-6 dpf (n=15, Welch's ANOVA $p<0.0001$, Games-Howell $p<.01$). **(c)** Representative images of regions of interest corresponding to viscera, trunk, and head regions across development. Scale bars = 500 μm.



Supplementary Figure 6:
Cryoprotectant and protease-inhibition properties of ABCL stabilization buffer. (a) 4 dpf wild-type larvae were homogenized in ABCL stabilization buffer containing 0% or 10% final concentration of sucrose and subjected to between 0 and 3 freeze-thaw cycles, and then separated using LipoGlo-electrophoresis as described in the methods section. While the lipoprotein size distribution remained constant in samples containing sucrose as a cryoprotectant, samples without sucrose showed a gradual enrichment of ZM particles, which appears to be due to aggregation of VLDL and IDL particles. **(b)** Larvae were homogenized in ABCL stabilization buffer with and without the protease inhibitor components (cOmplete mini EDTA-free tablet supplemented with 40 mM final concentration of EGTA, see recipes) and incubated at various temperatures for 2 hours. Samples were then separated by LipoGlo-electrophoresis at 50 V for 30 minutes, and 125 V for 60 minutes. This is 125 Volt-hours less than described in the methods section to enable visualization of proteolysis products. At 3 dpf, protease activity is quite low such that no proteolyzed products are present in the group treated with protease inhibitor, whereas degradation products are visible in a temperature-dependent manner in the absence of inhibitors. By 5 dpf, protease activity is much higher in the homogenate sample, presumably due to development of a mature intestine. Protease activity is still well-controlled in the presence of protease inhibitor at low temperatures, but in the absence of protease inhibitor degradation is so severe that there are signs of both cleavage of NanoLuc from the lipoprotein particle as well as proteolysis of the reporter itself.



Supplementary Figure 7:
NanoLuc standard curves. (a) To determine the absolute concentration of ABCLs in the larval homogenate, purified NanoLuc protein was ordered directly from Promega (Nluc-HT Protein, 500ug, 54.2KDa, #CS188401) and diluted to 1 nM working concentration in 1x ABCL stabilization buffer. This solution was subjected to a 6-point series of 2-fold dilutions and used in a plate-based assay for NanoLuc activity, and **(b)** luminescent signal showed excellent linear correlation with protein concentration within this concentration range (R^2=.97). **(c)** Plate reads were repeated in a kinetic experiment reading well values every 40 seconds for 20 minutes. Signal decayed only marginally in this time window, and half-lives were calculated to be greater than 60 minutes for all concentrations tested. **(d)** There is a marked increase in pigmentation throughout larval development, causing homogenate to become progressively more opaque. To test the effect of pigment on NanoLuc readings, wild-type larvae that lack the ApoB-NanoLuc reporter were homogenized in ABCL stabilization buffer at each day of larval development. This homogenate was then supplemented with a final concentration of 1 nM NanoLuc protein and subjected to a plate read assay. As expected, the relative intensity of NanoLuc signal declines from 1 – 6 dpf, indicating that absolute quantitation of NanoLuc levels should include a standard curve that accounts for changes in larval pigmentation.

Primer #	Purpose	Sequence
1	generate pME NanoLuc F	GGG GAC AAG TTT GTA CAA AAA AGC AGG CTT GAT GGT CTT CAC ACT CGA AGA TTT C
2	generate pME NanoLuc R	GGG GAC CAC TTT GTA CAA GAA AGC TGG GTT TAC GCC AGA ATG CGT TCG CA
3	generate left homology arm F	GGG GAC AAC TTT GTA TAG AAA AGT TGC GCT GCC TGG AAT GAA TGA AGC
4	generate left homology arm R	GGG GAC TGC TTT TTT GTA CAA ACT TGT CTG GAA AAA TGG GAG AGG AAG
5	generate right homology arm F	GGG GAC AGC TTT CTT GTA CAA AGT GGA ATA TGG TCA TTC TGA ACA GAA AGT AAA
6	generate right homology arm R	GGG GAC AAC TTT GTA TAA TAA AGT TGG GTA AGG CAG ACA TCA GTT TGT AAG
7	test TALEN cutting efficiency F	TGC AAT GAA GCA AAT CGA AAG TC
8	test TALEN cutting efficiency R	AAG ATT GGG TCG TGT TGC AT
9	genotype LipoGlo F	GCT TCC TCT CCC ATT TTT CC
10	genotype LipoGlo R1	CCC CGA GAT TCT GAA ACA AAC
11	genotype LipoGlo R2	AAG TGT CCA TTG GCT TCG AT
12	genotype mtp F	GTC TGA GGT TCA GAT GTA CCT GTT AGG AC
13	genotype mtp R	CTC TGC TGT GAT GAG CGC AGG
14	genotype apoc2 F	GAG CGG AGA GCT TTC GTG T
15	genotype apoc2 R	CTT CCA GCT TGT AGC CCT TG
16	genotype pla2g12b F	ACA AGG GAA AGC AAA CCA AA
17	genotype pla2g12b R	CAG TGT TGT ACA TGG TGT CTG C

Supplementary Table 1:
Primers used in this study.